Corvus funded into 2028 as soquelitinib studies continue recruiting
Cash of $202.9m supports a late-stage lymphoma trial and an eczema study, while a planned FDA meeting could broaden the company's ALPS effort.
Corvus Pharmaceuticals ended the third quarter with $202.9m in cash, which it says should finance operations until the second quarter of 2028. The figure came with its results on 5 November, alongside an update on soquelitinib, its ITK inhibitor.
The company is still enrolling patients in two studies of the drug: a Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma (PTCL) designed to be registrational, and a Phase 2 trial in atopic dermatitis. Because the PTCL study has not finished recruiting, there are no pivotal efficacy data yet, and the timing of any regulatory filing has not been set out.
Further immune-disease work is being run in China by Corvus's partner, Angel Pharma. Data from the first cohort in atopic dermatitis are due in March 2027, hidradenitis suppurativa data in the first half of 2027, and a Phase 2 asthma trial is expected to begin by the end of the first quarter of 2027. Each of those dates falls inside the period the company's cash is meant to cover.
Corvus also intends to meet the US Food and Drug Administration to discuss extending its ALPS programme to more centres and to paediatric patients. The material available gave no detail on the programme's current scope or on when the meeting will take place.
Why it matters
- The stated cash horizon of Q2 2028 extends beyond every partner readout and trial start currently scheduled.
- With the Phase 3 PTCL study still enrolling, soquelitinib has no pivotal data yet and no filing timeline.
- Angel Pharma's atopic dermatitis cohort 1 data in March 2027 are the next clinical readout in the China-based programme.
- The outcome of the FDA discussion on ALPS, including any paediatric expansion, is worth tracking.
Company's press release (SEC filing): Corvus Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
